<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METROGELÂ - metronidazoleÂ gelÂ </strong><br>Galderma Laboratories, L.P.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use METROGEL (metronidazole) Gel, 1% safely and effectively.
See full prescribing information for METROGEL (metronidazole) Gel, 1%
METROGELÂ® (metronidazole) Gel, 1%
For topical use only.
Initial U.S. Approval 1963</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>METROGELÂ® (metronidazole) Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>. (<a href="#section-">    1</a>)</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Not for oral, ophthalmic or intravaginal use. (<a href="#dosage-and-admin"> 2</a>)<br>
</li>
<li>Apply and rub in a thin film of METROGEL once daily to affected area(s). (<a href="#section-3">  2</a>)</li>
<li>Treated areas should be cleansed before the application of METROGEL. (<a href="#section-3">  2</a>)</li>
<li>Cosmetics may be applied after the application of METROGEL. (<a href="#section-3">  2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Gel, 1%.<br>  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">METROGEL is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or to any other ingredient in this formulation. (<a href="#contraindications"> 4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, characterized by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole,
<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> has been reported with the post approval use. The
appearance of abnormal neurologic signs should prompt immediate
reevaluation of METROGEL therapy. (<a href="#warnings-and-precautions"> 5.1</a>)</li>
<li>Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>. (<a href="#warnings-and-precautions"> 5.2</a>)</li>
<li>If <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> occurs, patients may need to discontinue use.Â  (<a href="#warnings-and-precautions"> 5.3</a>)</li>
<li>Topical metronidazole has been reported to cause tearing of the eyes.Â  Therefore, contact with the eyes should be avoided. (<a href="#warnings-and-precautions"> 5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt; 2%) are <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#adverse-reactions"> 6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Galderma Laboratories, L.P. at 1-866-735-4137, or FDA at 1-800-FDA-1088 orÂ  www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.Â  Drug interactions should be kept in mind when METROGEL is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. (<a href="#section-">   7</a>) </p></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Neurologic Disease</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications-and-usage"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>METROGEL<span class="Sup">Â®</span> is indicated for the topical treatment of inflammatory lesions of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage-and-admin"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply and rub in a thin film of METROGEL once daily to affected area(s).</p>
<p>A gentle cleanser should be used before the application of METROGEL.</p>
<p>Cosmetics may be applied after the application of METROGEL.</p>
<p>Not for oral, ophthalmic or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Gel, 1%.Â  METROGEL is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow gel.Â  Each gram of METROGEL contains 10mg (1%) of metronidazole.<br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">METROGEL is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or to any other ingredient in the formulation.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="warnings-and-precautions"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Neurologic Disease</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, characterized by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> has been reported with the post approval use. The appearance of abnormal neurologic signs should prompt immediate reevaluation of METROGEL therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Dyscrasias</span></h2>
<p class="First">Metronidazole is a nitroimidazole; use with care in patients with evidence of, or history of, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span></h2>
<p class="First">Irritant and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> have been reported.Â  If <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> occurs, patients may need to discontinue use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye Irritation</span></h2>
<p class="First">Topical metronidazole has been reported to cause tearing of the eyes.Â  Avoid contact with the eyes.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse-reactions"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br>In a controlled clinical trial, 557 patients used metronidazole gel, 1% and 189 patients used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of â‰¥1%:</p>
<a name="iaf273434-c8d2-4878-846f-7149b1693e76"></a><table width="90%">
<caption><span>Table 1: Adverse Reactions That Occurred at a Rate of â‰¥1%</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Metronidazole Gel, 1%</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Gel Vehicle</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N= 557</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N= 189</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Patients with at least one AE<br>Â Â Â Â Â Â  Number (%) of Patients</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">186 (33.4)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">51 (27.0)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">76 (13.6)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">28 (14.8)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 (1.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">17 (3.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 (4.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 (1.4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">14 (2.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4 (2.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">mycosis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">19 (3.4)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">5 (2.6)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Neoplasms</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">4 (0.7)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">2 (1.1)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Basal cell carcinoma</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">18 (3.2)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">3 (1.6)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">12 (2.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">22 (3.9)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">5 (2.6)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">36 (6.5)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">12 (6.3)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (1.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (1.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">8 (1.4)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">1 (0.5)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
</tbody>
</table>
<a name="if33eabd7-ec1c-4af8-82f1-49ed261a2337"></a><table width="90%">
<caption><span>Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline</span></caption>
<colgroup>
<col width="50%">
<col width="25%">
<col width="25%">
</colgroup>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Metronidazole Gel, 1%</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Gel Vehicle</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Sign/Symptom</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N= 544</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">N= 184</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Dryness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">138 (25.4)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">63 (34.2)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">93 (17.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">41 (22.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">42 (7.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20 (10.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (0.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Scaling</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">134 (24.6)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">60 (32.6)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">88 (16.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32 (17.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">43 (7.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">27 (14.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (0.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">86 (15.8)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">35 (19.0)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">53 (9.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21 (11.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">27 (5.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13 (7.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span>/burning</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">56 (10.3)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">28 (15.2)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="center">39 (7.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18 (9.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7 (1.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9 (4.9)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Â Â  Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10 (1.8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (0.5)</td>
</tr>
</tbody>
</table>
<p>The following additional adverse experiences have been reported with the topical use of metronidazole: <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, metallic taste, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of extremities</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Post Marketing Experience</h2>
<p class="First">The following adverse reaction has been identified during post approval use of topical metronidazole: <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.Â  Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="drug-interactions"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Drug interactions should be kept in mind when METROGEL is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<br><div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects:</span> Pregnancy Category B.<br><br>There are no adequate and well-controlled studies with the use of METROGEL in pregnant women.<br><br>Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole in rats or mice at 200 and 20 times, respectively, the expected clinical dose. However, oral metronidazole has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, METROGEL should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels taken after topical metronidazole application are significantly lower than those achieved after oral metronidazole a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the risk to the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Sixty-six subjects aged 65 years and older were treated with metronidazole gel, 1% in the clinical study.Â  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There are no reported human experiences with overdosage of METROGEL. Topically applied metronidazole can be absorbed in sufficient amount to produce systemic effects.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">METROGEL (metronidazole) Gel, 1% contains metronidazole, USP. Chemically, metronidazole is 2-methyl-5-nitro-1 <span class="Italics">H</span>-imidazole-1-ethanol. The molecular formula for metronidazole is C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span>. It has the following structural formula:</p>
<p><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe&amp;name=metronidazole-struc-1.jpg"></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p>Metronidazole has a molecular weight of 171.16. It is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20ËšC. Metronidazole belongs to the nitroimidazole class of compounds.<br><br>METROGEL is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, aqueous gel; each gram contains 10 mg of metronidazole in a base of betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<br><div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of metronidazole in the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The pharmacodynamics of metronidazole in association with the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> are unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Topical administration of a one gram dose of METROGEL to the face of 13 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> once daily for 7 days resulted in a mean Â± SD C<span class="Sub">max</span> of metronidazole of 32 Â± 9 ng/mL.Â  The mean Â± SD AUC<span class="Sub">(0-24)</span> was 595 Â± 154 ng*hr/mL. The mean C<span class="Sub">max</span> and AUC<span class="Sub">(0-24)</span> are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (T<span class="Sub">max</span>) was 6-10 hours after topical application.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<br><div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats, but not in studies involving hamsters.<br><br>In several long-term studies in mice, oral doses of approximately 225 mg/m<span class="Sup">2</span>/day or greater (approximately 37 times the human topical dose on a mg/m<span class="Sup">2</span> basis) were associated with an increase in pulmonary tumors and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses &gt;885 mg/m<span class="Sup">2</span>/day (144 times the human dose).<br><br>Metronidazole has shown evidence of mutagenic activity in several <span class="Italics">in vitro</span> bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was reported in patients with Crohn's disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was observed in patients with Crohn's disease treated with the drug for 8 months.<br><br>In one published study, using albino hairless mice, intraperitoneal administration of metronidazole at a dose of 45 mg/m<span class="Sup">2</span>/day (approximately 7 times the human topical dose on a mg/m<span class="Sup">2</span>/day basis) was associated with an increase in ultraviolet radiation-induced skin carcinogenesis. Neither dermal carcinogenicity nor photocarcinogenicity studies have been performed with METROGEL or any marketed metronidazole formulations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a randomized, vehicle-controlled trial, 746 subjects with <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> were treated with metronidazole gel, 1% or gel vehicle once daily for 10 weeks.Â  Most subjects had â€œmoderateâ€? <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> at baseline. Efficacy was determined by recording reduction in inflammatory lesion counts and success rate in the Investigator Global Assessment (percentage of subjects â€œclearâ€? and â€œalmost clearâ€? of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> at the end of the study). The scale is based on the following definitions:<br></p>
<a name="if1debd4d-823b-4297-8d76-22bc2d733ad5"></a><table width="90%">
<caption><span>Table 3: Investigator Global Assessment Scale</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Score</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Grade</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold">Definition</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Clear</td>
<td class="Botrule Lrule Rrule Toprule" align="left">No signs or symptoms present; at most, mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Almost Clear</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Very mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> present. Very few small <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Mild</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Mild <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.Â  Several small <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Moderate</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Moderate <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.Â  Several small or large <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, and up to 2 <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Severe</td>
<td class="Botrule Lrule Rrule Toprule" align="left">Severe <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.Â  Numerous small and/or large <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>/<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, up to several <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span></td>
</tr>
</tbody>
</table>
<br><p>The results are shown in the following table:<br><br></p>
<a name="i11aed736-44cb-4638-82b9-4bd27f356111"></a><table frame="box" width="90%">
<caption><span>Table 4: Inflammatory Lesion Counts and Global Scores in a Clinical Trial of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">Rosacea</span> </span></caption>
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Metronidazole Gel, 1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Vehicle</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Results N (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">N</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Results N (%)</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Inflammatory lesions</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">557</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">189</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Baseline, mean count</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">18.3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">18.4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Week-10, mean count</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">12.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Reduction</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">9.4 (50.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5.6 (32.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Investigator Global Assessment</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">557</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">189</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Subject clear or almost clear</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">214 (38.42)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">52 (27.51)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Subject with no change</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">159 (28.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">77 (40.7)</td>
</tr>
</tbody>
</table>
<p>Subjects treated with metronidazole gel, 1% experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.<br><br>The contribution to efficacy of individual components of the vehicle has not been established.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">METROGEL<span class="Sup">Â®</span> a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow in color, and is supplied as follows: <br><br>60 gram tube - <span class="Bold">NDC</span> 0299-3820-60</p>
<p>55 gram pump - <span class="Bold">NDC</span> 0299-3820-01<span class="Bold"></span><br></p>
<p><span class="Bold">Storage Conditions:</span> Store at controlled room temperature: 20Ëš to 25ËšC (68Ëš to 77ËšF), excursions permitted between 15Ëš and 30ËšC (59Ëš and 86ËšF).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="patients-counseling-info"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<br>Patients using METROGEL should receive the following information and instructions:<br><ol>
<li>This medication is to be used as directed.</li>
<li>It is for external use only.</li>
<li>Avoid contact with the eyes.</li>
<li>Cleanse affected area(s) before applying METROGEL.</li>
<li>This medication should not be used for any other condition than that for which it is prescribed.</li>
<li>Keep out of reach of children.</li>
<li>Patients should report any adverse reaction to their physicians.</li>
</ol>
<p class="First"><span class="Bold">RX Only</span></p>
<p>US Patent No. 6,881,726 and 7,348,317</p>
<p><br></p>
<span class="Bold">Manufactured by:</span><br>
G Production Inc.<br>
Baie d'UrfÃ©, Quebec, H9X 3S4 Canada<br>Made in Canada<br><br><span class="Bold">Marketed by:</span><br>
GALDERMA LABORATORIES, L.P.<br>
Fort Worth, Texas 76177 USA<br><p>Part Number</p>
<p><br><br></p>
<p><br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"></p>
<p></p>
<p></p>
<p><img alt="metrogel 60g tube carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe&amp;name=p50741-3-60g-tube-crtn.jpg"></p>
<p><span class="Bold">metro</span>gel 1%<br><br>(metronidazole gel), 1%<br><br><span class="Bold">NDC</span> 0299-3820-60<br><br><span class="Bold">Rx Only<br><br>NET WT. 60 g<br><br>GALDERMA</span><br><br><span class="Bold">For topical use only. Not for oral, ophthalmic or intravaginal use.</span><br><br>Store at controlled room temperature, 20Â° - 25Â°C (68Â° to 77Â°F), excursions permitted between 15Â° - 30Â°C (59Â° and 86Â°F). Keep out of reach of children.<br><br><span class="Bold">Ususal dosage:</span> Apply a thin film to the entire affected areas after washing once daily in the evening or as directed by the physician. Avoid applicaton close to the eyes.<br><br><span class="Bold">Each gram contains:</span> 10 mg (1%) metronidazole as active ingredient in a gel base consisting of betadex, edetate disodium, hydroxeyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben, and purified water.<br><br>US Patent No. 6,881,726 and 7,348,317<br><br>Marketed by:<br>GALDERMA LABORATORIES, L.P.<br>Fort Worth, Texas 76177 USA<br><br>Manufactured by:<br>G Production Inc.<br>Baie d'UrfÃ© Quebec H9X 3S4 Canada<br>Made in Canada.<br>www.metrogel.com</p>
<p>P50741-3<br></p>
<p><br>LOT:<br><br>EXP.:</p>
<br><br><p></p>
<p><img alt="metrogel 55g pump carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe&amp;name=p51727-1-55g-pmp-crtn.jpg"><br><span class="Bold"><br><span class="Bold"><span class="Bold">Rx OnlyÂ Â Â Â  </span><span class="Bold">NDC</span> 0299-3820-01</span></span></p>
<p><span class="Bold">metro</span>gel 1%<br><br>(metronidazole gel), 1%<span class="Bold"><br></span></p>
<p>PUMP</p>
<br><p>For topical use onlyÂ Â Â Â Â Â  NET WT. 55 g<br><span class="Bold"><br>GALDERMA</span><br><br><span class="Bold">For topical use only. Not for oral, ophthalmic or intravaginal use.</span><br><br>Store
at controlled room temperature, 20Â° - 25Â°C (68Â° to 77Â°F), excursions
permitted between 15Â° - 30Â°C (59Â° and 86Â°F). Keep out of reach of
children.<br><br><span class="Bold">Ususal dosage:</span> Apply a thin
film to the entire affected areas after washing once daily in the
evening or as directed by the physician. Avoid applicaton close to the
eyes.<br><br><span class="Bold">Each gram contains:</span> 10 mg (1%)
metronidazole as active ingredient in a gel base consisting of betadex,
edetate disodium, hydroxeyethyl cellulose, methylparaben, niacinamide,
phenoxyethanol, propylene glycol, propylparaben, and purified water.<br><br>US Patent No. 6,881,726 and 7,348,317<br><br>Marketed by:<br>GALDERMA LABORATORIES, L.P.<br>Fort Worth, Texas 76177 USA<br><br>Manufactured by:<br>G Production Inc.<br>Baie d'UrfÃ© Quebec H9X 3S4 Canada<br>Made in Canada.<br>GALDERMA is a registered trademark.</p>
<p>P51727-1<br></p>
<p><br>LOT:<br><br>EXP.:</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METROGELÂ 		
					</strong><br><span class="contentTableReg">metronidazole gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0299-3820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (Metronidazole) </td>
<td class="formItem">Metronidazole</td>
<td class="formItem">10Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>betadex</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>niacinamide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>phenoxyethanol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0299-3820-60</td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0299-3820-01</td>
<td class="formItem">55 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0299-3820-03</td>
<td class="formItem">3 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0299-3820-00</td>
<td class="formItem">3 g in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0299-3820-99</td>
<td class="formItem">55 g in 1 BOTTLE, PUMP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021789</td>
<td class="formItem">06/30/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Galderma Laboratories, L.P.
							(047350186)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">G Production Inc.</td>
<td class="formItem"></td>
<td class="formItem">251676961</td>
<td class="formItem">manufacture(0299-3820)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>578810bb-a90d-43bd-8c02-c33bdcfea68a</div>
<div>Set id: ab3a8a2d-714a-4beb-af8a-99bc3ac3ebbe</div>
<div>Version: 5</div>
<div>Effective Time: 20120601</div>
</div>
</div>Â <div class="DistributorName">Galderma Laboratories, L.P.</div></p>
</body></html>
